scindu funding
All calls

Portable and versatile Point-of-care diagnostics

Horizon Europe · Grant topic

HORIZON-HLTH-2027-02-IND-02-two-stage

Summary

A Polish company can use this call for R&D.

Funds portable and versatile point-of-care diagnostic tools for researchers and developers to accelerate accurate diagnosis and clinical decisions.

Who can apply
Companies can lead: SME, large company, research org, university.
Amount
€5M – €7M per projectTotal budget €39,300,000
Deadline
17 Feb 2027 01:00 CETin 116 days · +1 later cut-off
Status
Forthcomingopens 29 Oct 2026
Open on the portalRegister to keep this call

Machine-classified from the call text; check eligibility at the source.

Description

Expected Outcome:

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Maintaining an innovative, sustainable, and competitive EU health industry”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:

• Healthcare professionals dispose of diagnostic tools at the point of care that accelerate therapeutic decision making.

• Patients benefit from fast and accurate diagnosis leading to improved health outcomes.

• Thanks to more efficient diagnosis, health systems will get better evidence for disease control and prevention strategies.

Scope:

Point-of-Care (PoC) medical testing has made great technical progress (e.g. improved extraction, microfluidics, miniaturisation, and data processing techniques) with PoC test accuracies nearly matching those of lab-based tests. PoC tests may thus be an alternative to laboratory testing methods, enabling faster diagnostic results and therapeutic decision making. However, PoC testing is not always achieving a completely accurate diagnosis and one of the major issues with PoC diagnostics is the occurrence of false results during testing, another one is the often-cumbersome sample preparation. Hence there is a need for PoC diagnostics that are more sensitive, selective and easy-to-use allowing for improved clinical practice.

The World Health Organization (WHO) has defined a set of criteria for PoC diagnostics in primary care which, in the advent of digital technologies, has been completed with two additional features and is represented by the acronym REASSURED: Real-time connectivity, Ease of specimen collection and environmental friendliness, Affordable, Sensitive, Specific, User-friendly, Rapid and robust, Equipment-free (or equipment-modest) and Deliverable to end users. To these criteria adds the feature of “sample-to-answer” (sometimes also called “sample-to-result”) and more challenges like: Miniaturisation, power supply, versatility (nature and origin of the human sample), biocompatibility of the used materials and their suitability for mass production, readiness for high-throughput testing, quality control, regulatory compliance, environmental footprint and, last but not least, cost, which is of particular concern in resource-limited settings. All these challenges are not only valid for PoC diagnostics developed for infectious diseases, they equally apply to those that are designed to detect non-communicable diseases as well as their continuous monitoring on patients. Mobile technologies are playing an important role, especially since around 70% of the globally 7.4 billion cell phone users live in developing countries, which are the areas in direct need of advanced and more accessible PoC diagnostics (lower density of relevant health infrastructure, e.g. hospitals and laboratory medicine testing facilities). Mobile phones have not only been proposed and tested for data acquisition and readout of assays, images and other results but also for sample processing (e.g. for heating step), as have been Machine-Learning/Artificial Intelligence (ML/AI) powered algorithms that are integrated in the diagnostic devices to analyse complex biological data and detect patterns that might be missed by human analysis.

The selection of the PoC device to be developed or optimised should be based on an objectively conducted clinical needs assessment, which includes -next to clinicians’ perspectives- the complete care pathway and system-level needs. Moreover, a value-based concept should be applied in the choice and development of the PoC device, taking into account its Health Technology Assessment (HTA) by the relevant HTA bodies, in order to facilitate their decisions for adoption.

Proposals should be driven by a clear clinical need, integrate a value-based concept and include all the following activities:

• The optimisation of (the) targeted PoC diagnostic device(s) that take(s) the above-mentioned criteria, challenges and aspects into consideration.

• The elaboration of a comparative study clearly demonstrating the added value and improved performance of the optimised PoC diagnostic device(s) as compared to the current state of the art for the targeted diagnostic application.

• The conduct of clinical studies of (the) optimised PoC diagnostic medical device(s) as a preferred information source for their clinical validation; subsequent conformity assessment in agreement with requisite EU’s In-Vitro Medical Device (IVDR) or Medical Device (MDR) regulatory requirements.

In general, priority should be given to approaches that are suitable for resource-limited settings. In case of targeting infectious diseases, priority should be given to approaches enabling the distinction between viral, bacterial or fungal infections. In case of targeting non-communicable diseases, priority should be given to approaches that are used in emergency cases where decisions can have life-saving character.

Applicants invited to the second stage and envisaging to include clinical studies[1] should provide details of their clinical studies in the dedicated annex using the template provided in the submission system.

[1] Please note that the definition of clinical studies (see introduction to this Work Programme part) is broad and it is recommended that you review it thoroughly before submitting your application.

Who can apply, in detail
Applicant types
SME, Large company, Research org, University
Purpose
Research and innovation
R&D relevance
3 of 3
Poland eligible
Yes
Country limit
—
Region
Any
Consortium
Unclear
Readiness level (TRL)
—
Topics
  • Point-of-care diagnostics
  • Portable medical testing
  • Microfluidics
  • Miniaturisation
  • Diagnostic data processing

Machine-classified from the call text; check eligibility at the source. 23 Oct 2026

Conditions42

Typed facts extracted from the source documents by Scindu's grant-data review. Each value keeps its own conditions. Unknown means unstated, not zero or unlimited.

Applicant restriction
Participation and funding eligibility are distinct. Eligible participation remains subject to the Horizon Europe Regulation and topic conditions. Beneficiaries and affiliated entities register in the Participant Register before submission to obtain a PIC; legal validation and proof of legal status/origin are completed before grant signature, but a validated PIC is not a submission prerequisite. Associated partners may participate subject to the topic without signing the GA or charging costs/claiming contributions. General funding categories include EU Member States (including outermost regions), Overseas Countries and Territories, Associated Countries, and the listed low-/middle-income countries. Other entities receive funding only where the topic provides or the granting authority finds participation essential. Check applicable country status/list and call-specific exceptions. The general consortium default, unless specific call/topic conditions provide otherwise, is three mutually independent beneficiary legal entities established in three different countries: at least one in a Member State and two others each in different Member States or Associated Countries. Affiliated entities do not count toward this minimum. The JRC, international European research organisations and entities created under EU law are treated as established in a Member State different from those of other participants. Training/mobility and CoFund applications may be submitted by one or more entities if one is established in a Member State or Associated Country. Apply the three-beneficiary default only subject to any express own-topic exception; none is inferred from action-class wording alone.
Applicant restriction
For this assigned topic the source-bound action class is IA. Apply the general China rule by that class: the IA bar applies to IA; the default RIA bar and its listed exceptions apply only to RIA and only for the matching Work Programme destination. Do not transpose either rule to CSA, PCP or CoFund. The all-action MIIT-supervised Chinese public-university exclusion remains applicable. General Annex B: China-established legal entities are excluded from every IA and, unless stated otherwise, every RIA. The listed RIA destination exceptions are Cluster 2: Innovative Research on Democracy and Governance; Innovative research on European cultural heritage and cultural and creative industries; Innovative research on social and economic transformations. Cluster 5: Climate sciences and responses for the transformation towards climate neutrality. Cluster 6: Biodiversity and ecosystem services; Fair, healthy and environment-friendly food systems; Clean environment and zero pollution; Land, ocean and water for climate action; Resilient, inclusive, healthy and green rural/coastal/urban areas; and Innovative governance, environmental observations and digital solutions in support of the Green Deal. Missions: EU Missions’ Joint Calls; Adaptation to Climate Change; Restore our Ocean and Waters; and A Soil Deal for Europe. Widening: Widening participation and spreading excellence; Reforming and enhancing the European research and innovation system. New European Bauhaus Facility: Connecting the green transformation, social inclusion and local democracy; Innovative funding and new business models for neighbourhood transformation. Horizontal Activities: Transformative change towards a nature-positive economy and society. The listed destination exceptions are RIA exceptions only: they do not lift the China-established-entity exclusion for an IA. For an RIA, a China-established entity is excluded unless this call’s exact destination is one of the listed RIA exceptions; only when the destination matches may the entity participate in any capacity. A justified case-by-case exception may also be granted under the source rule. For IA and RIA restrictions that apply, exclusion covers participation in any capacity. MIIT-supervised Chinese public universities remain ineligible for any action. Evaluate this packet’s own action and exact destination before applying an exception. Entities subject to EU restrictive measures are not eligible in any capacity, including beneficiaries, affiliated entities, associated partners, third parties giving in-kind contributions, subcontractors or recipients of FSTP. Entities established in Russia, Belarus or non-government-controlled territories of Ukraine are likewise ineligible in any capacity even when not subject to EU restrictive measures; a justified case-by-case exception may be granted. Russian-established persons/entities/bodies whose direct or indirect proprietary rights exceed 50% in an entity established outside Russia make that entity ineligible in any capacity. These rules are distinct from call-specific ownership/control restrictions, which apply only when identified in the relevant Work Programme/topic conditions. Communications-network supplier restrictions and critical-technology/control restrictions apply only when identified in the relevant work-programme/topic conditions; they are not automatic for every call. Russian-established persons/entities/bodies that directly or indirectly hold proprietary rights exceeding 50% in an entity established outside Russia make that entity ineligible in any capacity. Hungarian public-interest trusts established under Act IX of 2021 and entities they maintain may apply, but while Council measures remain in force cannot take any funded role (including beneficiaries, affiliated entities, subcontractors, or recipients of FSTP); in multi-beneficiary calls the applicant is invited to remove/replace them from funded roles or change them to associated-partner status, with tasks and budget redistributed accordingly. Affected entities can participate without EU funding as associated partners if call conditions allow. These conditions do not establish eligibility for any particular participant.
Applicant restriction
Financial capacity is normally checked for the coordinator when requested grant is at least EUR 500,000, with exceptions for public bodies/international organisations and individual requested amounts no more than EUR 60,000. Checks may extend to other applicants, affiliated entities or guarantors; weak capacity can lead to safeguards or rejection. Operational capacity is assessed through the implementation award criterion; the form requests participant/researcher identity, up to five relevant achievements and up to five relevant prior projects/activities per participant, plus significant infrastructure/equipment. Public bodies, Member State organisations and international organisations are exempt from that operational-capacity check. Administrative sanctions and listed exclusion grounds bar participation, including insolvency, tax/social-security breaches, grave professional misconduct, fraud/corruption/criminal and financial-integrity offences, serious prior grant/contract failures, irregularities, circumvention and unremediable procurement-preparation conflicts; misrepresentation/non-supply and irremediable equality-of-treatment distortion are also refusal grounds. These legal/capacity checks are separate from award scores and do not certify a specific participant.
Applicant restriction
Entities in eligible countries that are directly/indirectly controlled by China or a Chinese legal entity are excluded under the topic critical-technology IA restriction.
Applicant restrictionAdopted General Annex B; only if the own-topic action activates this restriction
Where the specific action is expressly identified as subject to restrictions for protection of European communication networks, entities assessed as high-risk suppliers of mobile network communication equipment and entities they own or control are ineligible as beneficiaries, affiliated entities or associated partners. Assessment includes third-country interference/ownership/governance/business/legal context, supply-chain cybersecurity practices and relevant security assessments. Exceptions may be requested from the granting authority, which assesses them case by case using the 5G toolbox criteria, security risks and availability of alternatives in the action. This conditional general clause does not activate the restriction for an unflagged topic or extend the listed participation roles.

Own-topic activation and other separately stated country/control restrictions retain their distinct scope.

Applicant restriction
General Annex B restrictions apply, including the default exclusion of entities established in China from Health RIAs, participation of MIIT-supervised Chinese universities, EU restrictive measures, and the applicable Hungarian public-interest-trust restriction. Exceptions/changes require individual checking; the US funding exception does not waive other restrictions.
Applicant type
Legal entities subject to Horizon Europe Regulation, General Annex B and topic-specific conditions; participation does not itself establish eligibility for funding.
Application restriction
Submit electronically using the forms in the Portal system (topic-page templates are informational), following the form instructions. Applications must include all parts and mandatory annexes/supporting documents and be readable, accessible and printable. Full applications include an exploitation/dissemination/communication plan unless the topic provides otherwise; no such plan is required for stage 1 of a two-stage process. Where relevant, include a commercial exploitation strategy; where exploitation is primarily in non-associated third countries, explain why it is in the EU interest. General Annex A defaults: full application 40 pages, except CSA 25 and Programme Co-fund 65; for lump-sum topics RIA/IA 45 and CSA 28; stage 1 is 10 pages. The specific topic and actual Portal form/template override defaults. Blind first-stage anonymisation applies only when the topic specifies blind evaluation. If an application exceeds the applicable page limits, the submission system gives an automatic warning and invitation to resubmit a conforming version. After the call deadline, excess pages are automatically made invisible and are not considered by evaluators. Actual topic conditions and Portal submission templates govern the applicable limits and sections. This procedure does not promise a post-deadline correction window or say the whole application is automatically rejected.
Application restriction
Projects must focus exclusively on civil applications and comply with EU policy interests/priorities. Applicants complete an ethics self-assessment; projects raising ethics issues undergo ethics review and may receive ethics deliverables/authorisation requirements. Security appraisal/classified-information conditions apply only when classified or sensitive information is involved. A GEP is an eligibility requirement at grant signature and throughout the grant only for MS/AC public bodies, research organisations and higher-education establishments applying as beneficiaries or affiliated entities. It must be published, top-management-signed/adopted, resourced, monitor sex/gender-disaggregated data with reporting at least every two years, and include staff/decision-maker awareness or training; equivalent strategic documents can satisfy the process requirements. GEP eligibility does not apply to other legal-entity categories. Separately, beneficiaries must take measures to promote equal opportunities and, where applicable, follow the GEP; they should aim, to the extent possible, for gender balance at all personnel levels, including supervisory/managerial levels. This is an implementation aim, not a numerical staffing quota. A self-declaration is requested in the Participant Register. Source-listed GEP content areas are recommendations, not extra mandatory eligibility items.
Application restriction
First-stage evaluation is blind: omit organisation names/acronyms/logos and personnel names from abstract/PartB. Admission-budget target differs by topic and is not an award guarantee.
Application restriction
First-stage admission cut-off is set near 4 times the available budget, with a lower bound of 3.5; it is a requested-budget multiplier, not a funding rate.
Application restrictionStage1 screening only for HORIZON-HLTH-2027-02-IND-02-two-stage
First-stage Excellence and Impact each require4points. Sum-score cutoff is dynamic for each indicative budget split: admitted requested budgets close to4times available budget and not below3.5times. GeneralAnnexD normally expects score8or8.5, subject to actual proposal volume and applicable own-topic screening exceptions. Full-stage scoring is distinct.

First stage only; Excellence and Impact only, and only aspects printed in bold in the criteria table. Overall summed threshold is set separately for each indicative budget split from actual proposal volume. Admitted requested budgets should be as close as possible to target multiplier, never below lower-bound multiplier. These are requested-budget/available-budget ratios, not grant rates, award counts or project budgets. Expected normal score8or8.5 is not a fixed universal cutoff. Own-topic budget multipliers override GeneralAnnexD generic3/2; other expressly adopted general rules retain their source modality.

Application restriction
Full applications: Excellence, Impact and Implementation each have threshold4/5, cumulative threshold12. Passing thresholds enters budget-limited ranking, not an award. Any own first-stage rules are additional and scoped separately.
Application restrictionHORIZON-HLTH-2027-02-IND-02-two-stage; adopted AnnexE, subject to stage-specific templates
Use the electronic Portal system and complete all parts, mandatory annexes and supporting documents. PartA contains organisation/administrative data, summary budget and call questions; PartB is the technical PDF description. Upload supporting documents in system-permitted formats. Design the proposal around the award criteria. Coordinator confirms mandate, correctness/completeness and all participants’ eligibility/capacity/exclusion compliance; each participant reconfirms by declaration of honour before signature. Noncompliance can cause rejection and later legal-entity/financial/bank validation documents may be requested. Actual stage-specific Portal templates and own-topic conditions govern.
Application restrictionEvaluation review; actual/deemed access anchors, not submission or project deadlines
Coordinator may request review of procedural flaws, following evaluation-result-letter procedures/deadlines; merits are not reviewed. Each request concerns one specific proposal, within30days after opening/access of results, maximum7000characters. Notifications unopened for10days after sending are deemed accessed. A review committee may recommend re-evaluation, primarily by experts not involved previously, or confirmation of the initial evaluation.
Application restrictionDefault full-application ranking within one budget envelope; own special arrangements retained
Adopted General Annex F default for proposals with the same score within one budget envelope, excluding stage 1 of two-stage submissions and subject to any specific call/topic special arrangement: first prioritise call aspects not covered by more highly ranked proposals. Those identified proposals are then prioritised by Excellence and then Impact; for Innovation Actions the order is Impact then Excellence. If necessary, use gender balance among named leading researchers; then geographical diversity by MS/AC not otherwise receiving funds from higher-ranked projects (number first, then budget if equal). If still indistinguishable, the panel may use documented call/Horizon-objective factors, for example project-portfolio synergies or relevant feasible SME involvement. This is a priority procedure, not a funding guarantee, staffing quota or first-stage tie rule.
Application restriction
Own-topic first-stage Excellence and Impact each have threshold4/5. Their summed cutoff is set to admit requested budgets as close as possible to4times available budget and not below3.5times. This is requested-budget screening, not a grant rate or promised number of awards. Full-stage thresholds remain4/4/4and12.
Application restriction
Planned opening 2026-10-29; first-stage deadline 2027-02-17; second-stage deadline 2027-09-16; 17:00 Brussels local time. Work Programme allows opening shifts and deadline delays; live acceptance is not verified.
Consortium required
Yes
Eligible geography
General Annex B funding-geography conditions apply, with the topic-specific exception allowing US legal entities to receive Union funding. Participation and funded status remain distinct; restrictive measures and applicant-specific conditions still apply.
Eligible project scope
Clinical-needs/value/HTA concept, optimisation, a comparative added-value study, clinical validation and appropriate IVDR/MDR conformity assessment are all part of the requested programme.
Eligible project scope
The source describes the REASSURED design criteria: Real-time connectivity; Ease of specimen collection and environmental friendliness; Affordable; Sensitive; Specific; User-friendly; Rapid and robust; Equipment-free (or equipment-modest); Deliverable to end users. It also identifies sample-to-answer, miniaturisation, power supply, versatility of sample nature/origin, biocompatibility and mass-production suitability, high-throughput readiness, quality control, regulatory compliance, environmental footprint and cost as challenges for both infectious and non-communicable disease testing/monitoring. These are design criteria and technical challenges to consider; the topic does not state that every project must solve each item independently.
Eligible project scope
The topic seeks more sensitive, selective, accurate and easy-to-use point-of-care (PoC) medical diagnostics with less cumbersome sample preparation, improving clinical practice and therapeutic decisions. Device selection/optimisation should be based on an objective clinical-needs assessment including clinicians, the complete care pathway and system-level needs, and a value-based concept considering assessment by relevant HTA bodies to facilitate adoption decisions. Proposals should be driven by clear clinical need, integrate value-based considerations, and include all three activities: (1) optimise targeted PoC devices against the stated criteria/challenges; (2) conduct a comparative study demonstrating added value and improved performance versus state of the art for the targeted application; (3) conduct clinical studies of the optimised PoC medical device as the preferred clinical-validation information source, followed by conformity assessment under applicable IVDR/MDR requirements. Relevant technical/design considerations include REASSURED features (real-time connectivity; ease of specimen collection and environmental friendliness; affordability; sensitivity; specificity; user-friendliness; rapid/robust operation; equipment-free/modest operation; deliverability to end users) plus sample-to-answer, miniaturisation, power, sample versatility, biocompatibility/material suitability for mass production, high-throughput readiness, quality control, regulatory compliance, environmental footprint and cost. Priority should generally be given to resource-limited settings; for infectious disease, priority should enable viral/bacterial/fungal distinction; for NCDs, priority should concern emergency/life-saving decisions.
Expected number of grants (planning estimate)Captured SEDIA planning estimate for exact topic HORIZON-HLTH-2027-02-IND-02-two-stage
6 count

Expected funded-project/grant count in the exact provider topic budgetOverview. Indicative planning metadata, not guaranteed awards, maximum accepted projects, staffing or consortium size. It does not replace any differently expressed work-programme planning range.

Other condition
The exact topic adopts General Annex G, subject to its expressly listed exceptions. The signed grant fixes the final amount, eligible costs, model, duration and reporting arrangements.
Other condition
For this explicitly lump-sum topic, evaluators provide comments on the detailed lump-sum budget table in the Evaluation Summary Report only for proposals invited to grant-agreement preparation, proposals placed on the reserve list, and proposals rejected (in part) because costs were significantly overestimated or underestimated. This limits ESR budget-table comments; it does not change the funding model or imply that comments are otherwise a condition of award.
Other condition
Project starting date and duration are fixed in the grant agreement. No numerical duration is asserted from the indicative funding table.
Other conditionHORIZON-HLTH-2027-02-IND-02-two-stage; IA full-application award aspects; not first-stage full-rubric scoring
For IA full applications evaluated under adopted AnnexD, assess the action-specific qualitative aspects. Excellence: clarity/pertinence of objectives and ambition beyond the state of the art; sound methodology, including underlying concepts/models/assumptions, interdisciplinary approaches, appropriate research-content gender dimension, and quality of open-science practices including research-output sharing/management and citizen/civil-society/end-user engagement where appropriate. Impact: credible pathways to expected work-programme outcomes/impacts; suitable, high-quality measures to maximise them through the dissemination/exploitation plan, including communication. Implementation: effective, high-quality work plan, risk assessment, appropriate work-package effort and overall resources; each participant’s capacity/role and the consortium’s necessary expertise. Aspects are considered to the extent relevant to the work-programme description; scores are for criteria, not separate scores for each aspect. Own-topic exceptions and the separately recorded stage-specific score rules retain priority.
Other conditionHORIZON-HLTH-2027-02-IND-02-two-stage; first-stage RIA/IA qualitative evaluation only
At stage1 only the bold AnnexD Excellence/Impact aspects are assessed: objectives’ clarity/pertinence and ambition beyond the state of the art; soundness of the overall methodology as framed in the first-stage template, which includes gender integration and open-science practices; and credible pathways to expected outcomes/impacts. Do not score the full-application dissemination/exploitation-plan or Implementation aspects as separate stage1 requirements. Own-topic first-stage exceptions, any expressly adopted blind rule, and the independently captured numeric thresholds/budget-admission test retain priority; this fact changes none of those numeric rules.
Other conditionGeneral Annex F default limitations; individual part budget denominator and call-specific procedures
Invitation to grant preparation is no formal funding commitment; legal/capacity/exclusion checks remain. Call/topic budgets are indicative; unless otherwise stated final figures may change up to20% relative to the total budget in each individual work-programme part, not an automatic project or topic increase. Seals of Excellence/STEP seals, joint-call selection, blind first-stage evaluation and partial randomisation depend on explicit own-call conditions; none follows automatically from two-stage status. The tie method in points1–4 is reapplied to remaining equally ranked proposals.
Other conditionDefault indicative evaluation/grant-preparation timetable; own-topic timeline prevails
Absent different own-call conditions, evaluation outcome is around5months after submission deadline and grant signature around8months. Two-stage default: around3months from stage1deadline for its outcome; around5months from stage2deadline for its outcome, and around8months from stage2deadline for grant signature. Indicative planning estimates, not fixed promises or project/employment duration.
Other conditionHORIZON-HLTH-2027-02-IND-02-two-stage; adopted General Annex G baseline subject to express own-topic grant provisions and actual agreement
Grant preparation with the EU project officer sets deliverables, reporting/payments, grant amount, rate, eligible costs and duration in the agreement. Budget is EUR and award may be below request. Start normally follows signature; retroactive start and month-based duration extensions need exceptional justified granting-authority agreement. Portal manages milestones/deliverables reflected in agreementAnnex1. For ACTUAL-COST grants only eligible incurred costs are reimbursed at the agreed rate; surplus/profit is deducted and noncompliance may reduce grant. This conditional actual-cost description does not reclassify an expressly lump-sum/unit topic: its rate is already applied in amount-setting and does not appear as a separately added reimbursement percentage. Own-topic grant form/rate, PCPprocurement conditions and partnership amendment restrictions remain.
Other conditionHORIZON-HLTH-2027-02-IND-02-two-stage; adopted General Annex G baseline subject to express own-topic grant provisions and actual agreement
Agreement covers proper implementation, conflicts, confidentiality/security/classified information, ethics/integrity/values/gender, data protection, IPR/background/results/access/use, communication/dissemination/open science/visibility and applicable special action rules. Additional adopted duties: if granting authority requests during a public emergency, grant nonexclusive result licences on fair/reasonable terms for its stated limited period to entities committed to rapid broad exploitation; provision applies up to4years after action end. Unless own-call states otherwise, notify authority for up to4years after end when results could reasonably contribute to European/international standards. Authority may object to ownership transfer/exclusive licensing for up to4years after end ONLY where specific call provides. Give data/result access needed to validate publication conclusions while safeguarding legitimate interests/constraints unless access already given. On authority request in public emergency, immediately deposit research outputs and provide CC BY,CC0 or equivalent open access; where legitimate interests preclude this, provide the stated nonexclusive fair/reasonable licences instead, with that exception limited to4years after end. Breach/other legal violations may trigger agreementChapter5 measures; no unread AGA provisions or executed applicant agreement are asserted.
Other conditionHORIZON-HLTH-2027-02-IND-02-two-stage; adopted General Annex G baseline subject to express own-topic grant provisions and actual agreement
After signature, normal initial float is160% of average EU funding per reporting period: maximum grant amount divided by number of reporting periods. Exceptionally less or no pre-financing is possible. With ONLY ONE reporting period it will be less, since100% would already equal the whole grant; no fixed single-period percentage is specified. Programme co-fund actions may receive additional pre-financing. At pre-financing,5–8% of maximum grant is deducted into the mutual-insurance mechanism, not added as a benefit or treated as funding intensity. EU debts may offset/reduce payments. Interim payments link to periodic reports; final report determines final grant and overpayment is recovered. Financial-statement certificate thresholds depend on grant size/beneficiary type and the agreement, not an invented universal amount. Recovery liability is individual: beneficiary’s own and affiliated-entity debts. These normal/general arrangements do not guarantee a new payment on an existing partnership amendment or displace express own-topic/agreement provisions.
Other condition
Own-topic overview plans an indicative 6 projects expected to be funded; not job headcount or consortium size.
Other condition
Eligible costs explicitly take the form of a lump sum. Underlying cost estimates follow actual-cost eligibility and normal practices, but do not establish salary reimbursement or a personal stipend.
Other condition
Lump-sum interim payments pay accepted completed work-package shares; partial work-package payments are possible at final balance under the guide conditions.
Other condition
The topic says device selection should be based on an objective clinical-needs assessment including clinician perspectives, the full care pathway and system-level needs; the value-based approach should consider HTA by relevant bodies for adoption decisions. Proposals should include all three specified activities: device optimisation; a comparative added-value/performance study against state of the art; and clinical studies (the preferred validation information source), followed by IVDR/MDR conformity assessment. Priority should generally be given to resource-limited settings; in infectious-disease applications, priority should be given to distinguishing viral, bacterial or fungal infection; in NCD emergency applications, priority should be given where decisions may be life-saving. Applicants invited to stage two who envisage clinical studies should provide details in the dedicated submission-system clinical-studies annex/template.
Other condition
The topic expects all three outcomes: healthcare professionals have point-of-care diagnostic tools that accelerate therapeutic decisions; patients benefit from fast/accurate diagnosis and improved health outcomes; and more efficient diagnosis gives health systems better evidence for disease control and prevention.
Other condition
The granting authority may object to transfer of ownership or exclusive licensing of results up to four years after action end, under the specific Annex5 provision.
Other condition
When satellite observation, positioning, navigation or related timing data/services are used, use Copernicus and/or Galileo/EGNOS; other services/data may be additional.
Partner requirement
At least three independent beneficiary legal entities in three different countries: at least one in an EU Member State and at least two others in different EU Member States or Associated Countries. Affiliated entities do not count toward this minimum.
Amounts and costs9
Indicative budget
€39,300,000

Topic budget as stated in the portal's budget table. Lump-sum and per-project limits are in the call conditions.

Eligible costHORIZON-HLTH-2027-02-IND-02-two-stage; express lump-sum grant budget; applicable decision/template qualifications retained
For this expressly lump-sum topic, provide the detailed estimated budget table to justify/fix the lump sum, approximating costs actually incurred and satisfying basic EU actual-cost eligibility conditions. Purchases and subcontracting must ensure best value for money (or lowest price where appropriate) and be free of conflicts of interest. Ineligible table costs can reduce the grant even during implementation or after completion. Only an exceptional action-specific authorising decision may waive the detailed table. This is amount-setting/cost-eligibility methodology, not reimbursement of every actual expense or a salary entitlement.
Eligible costHORIZON-HLTH-2027-02-IND-02-two-stage; adopted General Annex G baseline subject to express own-topic grant provisions and actual agreement
Agreement fixes cost forms/categories: eligible actual personnel/subcontracting/purchases and FSTP only if call permits; units may cover personnel, SMEowners/naturalpersons without salary, usual-practice average personnel and internally invoiced goods/services, and expressly permitted specific units. The25%indirect-cost base excludes subcontracting,FSTP and units/lump sums already containing indirect costs. Different cost forms can coexist; global/action-category lump sums require call provision. Several EU Synergy grants may declare costs only where cumulative funding does not exceed100% of eligible costs/contributions declared. These are budget/eligibility methods, not personal salary or automatic FSTP/unit-cost permission; separately recorded own-topic costs/forms and rates retain priority.
Eligible cost
General Annex G includes personnel costs, subcontracting and purchases among eligible budget categories subject to the grant agreement. Personnel may use applicable actual-cost or unit-cost forms. This is a cost category, not an advertised vacancy, mandatory hire, salary scale, headcount or FTE entitlement.

For the explicit lump-sum topic, eligible personnel estimates help establish the lump sum; salary reimbursement is not asserted.

Funding intensity, maximumeligible nonprofit legal entities
100 percent of eligible costs

Distinct legal-entity case; for lump sums the rate is applied in amount setting, not payroll reimbursement.

Funding intensity, maximumordinary eligible legal entities
70 percent of eligible costs

Distinct legal-entity case; for lump sums the rate is applied in amount setting, not payroll reimbursement.

Indirect cost flat rateGeneralAnnexG indirect costs for this Horizon action/grant methodology
25 percent of the named eligible-direct-cost base

Base: total eligible direct costs excluding subcontracting, financial support to third parties and any unit costs/lump sums already including indirect costs. Apply only within the relevant grant/budget methodology; for lump sums this contributes to amount-setting, not an extra actual-cost payment or wage rate.

Expected project funding, up to
€7,000,000

Indicative expected contribution range; requests for different amounts may be submitted and selected. Not a hard minimum/cap.

Expected project funding, from
€5,000,000

Indicative expected contribution range; requests for different amounts may be submitted and selected. Not a hard minimum/cap.

Topic allocation
€39,300,000

Indicative total topic budget; not an individual cap, guaranteed award or current remaining balance.

Source documents3
Call facts
Opens
29 Oct 2026
Deadlines
  • 17 Feb 2027 01:00 CET
  • 16 Sept 2027 02:00 CEST
Deadline model
Two-stage
Programme
Horizon Europe · 2021 - 2027
Call
HORIZON-HLTH-2027-02-two-stage · Cluster 1 - Health (Two stage - 2027)
Types of action
HORIZON Innovation Actions
Keywords
  • POC
  • Point of care
  • Point-of-care
  • clinical trials
  • diagnostics
  • digital health
  • in-vitro diagnostic
  • medical device
Checked
23 Oct 2026
Portal updated
7 Oct 2026
Review status
Partial review
Reviewed
24 Oct 2026

This is a summary of the source page, not the official text. Eligibility, conditions and the submission system are at the source.